Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 20-Hydroxyecdysone SCHEMBL20033388 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL9481370 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193574 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL6243068 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193572 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL990951 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861138 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL17580332 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861142 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL3043993 | 1.00 | MEN1 (0.71) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | claimed |
| US-12551495-B2 | Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection | BIOPHYTIS (FR) | 2026-02-17 | — | — | US | claimed |
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| EP-4637780-A1 | PHYTOECDYSONES FOR USE IN THE TREATMENT OF INFLAMMATORY RESPIRATORY DISEASES | Biophytis (FR) | 2025-10-29 | — | — | EP | claimed |
| US-12440500-B2 | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | BIOPHYTIS (FR) | 2025-10-14 | — | — | US | claimed |
| EP-3758709-B1 | PHYTOECDYSONES FOR USE IN THE PREVENTION OF MUSCLE STRENGTH LOSS DURING IMMOBILISATION | BIOPHYTIS (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2025132808-A1 | COMPOSITIONS OF PHYTOECDYSONES FOR INTRANASAL ADMINISTRATION | BIOPHYTIS (FR) | 2025-06-26 | — | — | WO | claimed |
| US-20250207127-A1 | PHYTOECDYSONES AND/OR 20-HYDROXYECDYSONE DERIVATIVES IN COMBINATION WITH AN ACTIVE INGREDIENT FOR RESTORING SMN EXPRESSION, FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | KREOS CAPITAL VI (UK) LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| CN-115963199-B | Quantitative detection method and application of steroid hormone in human/animal body fluid | 上海鹿明生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2001062780-A1 | GENE EXPRESSION SYSTEM BASED ON CHIMERIC RECEPTORS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-08-30 | — | — | WO | claimed |
| EP-1112360-A1 | ECDYSONE RECEPTORS AND METHODS FOR THEIR USE | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2001-07-04 | — | — | EP | claimed |
| EP-1018885-A1 | INSECTICIDAL ENZYMES | Mycogen Corporation (US) | 2000-07-19 | — | — | EP | claimed |
| WO-2000015791-A1 | ECDYSONE RECEPTORS AND METHODS FOR THEIR USE | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2000-03-23 | — | — | WO | claimed |
| EP-0914610-A1 | SCREEN FOR ECDYSONE RECEPTOR LIGANDS | AMERICAN CYANAMID COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1997045731-A9 | SCREEN FOR ECDYSONE RECEPTOR LIGANDS | — | 1998-03-19 | — | — | WO | claimed |
| WO-1997045731-A1 | SCREEN FOR ECDYSONE RECEPTOR LIGANDS | AMERICAN CYANAMID COMPANY (US) | 1997-12-04 | — | — | WO | claimed |
| WO-1997020469-A1 | INSECTICIDAL ENZYMES | MYCOGEN CORPORATION (US) | 1997-06-12 | — | — | WO | claimed |
| EP-0740930-A1 | BLOOD FLOW IMPROVER AND COSMETIC | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1996-11-06 | — | — | EP | claimed |
| EP-0120799-A1 | Medicament and vaccine against helminth parasitization derived from an ecdysteroid compound | Société Anonyme dite: IMMUNOTECH (FR) | 1984-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | MTPN, UTRN, TTN | MEN1 4594/4885KMT2A 3665/4885 |
| US-12440500-B2 | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | SMN1; SMN2, PMP22, MUSK | MEN1 2067/4885KMT2A 2482/4885 |
| US-20250207127-A1 | PHYTOECDYSONES AND/OR 20-HYDROXYECDYSONE DERIVATIVES IN COMBINATION WITH AN ACTIVE INGREDIENT FOR RESTORING SMN EXPRESSION, FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PMP22, RBM17 | MEN1 2048/4885KMT2A 1119/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | MEN1 1373/4885KMT2A 1892/4885 |
| US-12551495-B2 | Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection | ACE2, TMPRSS2, ACE | MEN1 4399/4885KMT2A 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.